Safety and Immunogenicity Analysis of a Newcastle Disease Virus (NDV-HXP-S) Expressing the Spike Protein of SARS-CoV-2 in Sprague Dawley Rats
Despite global vaccination efforts, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to evolve and spread globally. Relatively high vaccination rates have been achieved in most regions of the United States and several countries worldwide. However, access to vaccines in low- and...
Guardado en:
| Autores principales: | , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Frontiers Media S.A.
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/5b32844202bb44e5b26127bad0eeb6d7 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:5b32844202bb44e5b26127bad0eeb6d7 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:5b32844202bb44e5b26127bad0eeb6d72021-11-18T09:23:52ZSafety and Immunogenicity Analysis of a Newcastle Disease Virus (NDV-HXP-S) Expressing the Spike Protein of SARS-CoV-2 in Sprague Dawley Rats1664-322410.3389/fimmu.2021.791764https://doaj.org/article/5b32844202bb44e5b26127bad0eeb6d72021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fimmu.2021.791764/fullhttps://doaj.org/toc/1664-3224Despite global vaccination efforts, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to evolve and spread globally. Relatively high vaccination rates have been achieved in most regions of the United States and several countries worldwide. However, access to vaccines in low- and mid-income countries (LMICs) is still suboptimal. Second generation vaccines that are universally affordable and induce systemic and mucosal immunity are needed. Here we performed an extended safety and immunogenicity analysis of a second-generation SARS-CoV-2 vaccine consisting of a live Newcastle disease virus vector expressing a pre-fusion stabilized version of the spike protein (NDV-HXP-S) administered intranasally (IN), intramuscularly (IM), or IN followed by IM in Sprague Dawley rats. Local reactogenicity, systemic toxicity, and post-mortem histopathology were assessed after the vaccine administration, with no indication of severe local or systemic reactions. Immunogenicity studies showed that the three vaccination regimens tested elicited high antibody titers against the wild type SARS-CoV-2 spike protein and the NDV vector. Moreover, high antibody titers were induced against the spike of B.1.1.7 (alpha), B.1.351 (beta) and B.1.617.2 (delta) variants of concern (VOCs). Importantly, robust levels of serum antibodies with neutralizing activity against the authentic SARS-CoV-2 USA‐WA1/2020 isolate were detected after the boost. Overall, our study expands the pre-clinical safety and immunogenicity characterization of NDV-HXP-S and reinforces previous findings in other animal models about its high immunogenicity. Clinical testing of this vaccination approach is ongoing in different countries including Thailand, Vietnam, Brazil and Mexico.Johnstone TcheouAriel RaskinGagandeep SinghHisaaki KawabataDominika BielakWeina SunIrene González-DomínguezD Noah SatherD Noah SatherD Noah SatherAdolfo García-SastreAdolfo García-SastreAdolfo García-SastreAdolfo García-SastreAdolfo García-SastrePeter PalesePeter PaleseFlorian KrammerFlorian KrammerJuan Manuel CarreñoFrontiers Media S.A.articleCOVID-19SARS-CoV-2newcastle disease virusvaccineimmunogenicitysafetyImmunologic diseases. AllergyRC581-607ENFrontiers in Immunology, Vol 12 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
COVID-19 SARS-CoV-2 newcastle disease virus vaccine immunogenicity safety Immunologic diseases. Allergy RC581-607 |
| spellingShingle |
COVID-19 SARS-CoV-2 newcastle disease virus vaccine immunogenicity safety Immunologic diseases. Allergy RC581-607 Johnstone Tcheou Ariel Raskin Gagandeep Singh Hisaaki Kawabata Dominika Bielak Weina Sun Irene González-Domínguez D Noah Sather D Noah Sather D Noah Sather Adolfo García-Sastre Adolfo García-Sastre Adolfo García-Sastre Adolfo García-Sastre Adolfo García-Sastre Peter Palese Peter Palese Florian Krammer Florian Krammer Juan Manuel Carreño Safety and Immunogenicity Analysis of a Newcastle Disease Virus (NDV-HXP-S) Expressing the Spike Protein of SARS-CoV-2 in Sprague Dawley Rats |
| description |
Despite global vaccination efforts, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to evolve and spread globally. Relatively high vaccination rates have been achieved in most regions of the United States and several countries worldwide. However, access to vaccines in low- and mid-income countries (LMICs) is still suboptimal. Second generation vaccines that are universally affordable and induce systemic and mucosal immunity are needed. Here we performed an extended safety and immunogenicity analysis of a second-generation SARS-CoV-2 vaccine consisting of a live Newcastle disease virus vector expressing a pre-fusion stabilized version of the spike protein (NDV-HXP-S) administered intranasally (IN), intramuscularly (IM), or IN followed by IM in Sprague Dawley rats. Local reactogenicity, systemic toxicity, and post-mortem histopathology were assessed after the vaccine administration, with no indication of severe local or systemic reactions. Immunogenicity studies showed that the three vaccination regimens tested elicited high antibody titers against the wild type SARS-CoV-2 spike protein and the NDV vector. Moreover, high antibody titers were induced against the spike of B.1.1.7 (alpha), B.1.351 (beta) and B.1.617.2 (delta) variants of concern (VOCs). Importantly, robust levels of serum antibodies with neutralizing activity against the authentic SARS-CoV-2 USA‐WA1/2020 isolate were detected after the boost. Overall, our study expands the pre-clinical safety and immunogenicity characterization of NDV-HXP-S and reinforces previous findings in other animal models about its high immunogenicity. Clinical testing of this vaccination approach is ongoing in different countries including Thailand, Vietnam, Brazil and Mexico. |
| format |
article |
| author |
Johnstone Tcheou Ariel Raskin Gagandeep Singh Hisaaki Kawabata Dominika Bielak Weina Sun Irene González-Domínguez D Noah Sather D Noah Sather D Noah Sather Adolfo García-Sastre Adolfo García-Sastre Adolfo García-Sastre Adolfo García-Sastre Adolfo García-Sastre Peter Palese Peter Palese Florian Krammer Florian Krammer Juan Manuel Carreño |
| author_facet |
Johnstone Tcheou Ariel Raskin Gagandeep Singh Hisaaki Kawabata Dominika Bielak Weina Sun Irene González-Domínguez D Noah Sather D Noah Sather D Noah Sather Adolfo García-Sastre Adolfo García-Sastre Adolfo García-Sastre Adolfo García-Sastre Adolfo García-Sastre Peter Palese Peter Palese Florian Krammer Florian Krammer Juan Manuel Carreño |
| author_sort |
Johnstone Tcheou |
| title |
Safety and Immunogenicity Analysis of a Newcastle Disease Virus (NDV-HXP-S) Expressing the Spike Protein of SARS-CoV-2 in Sprague Dawley Rats |
| title_short |
Safety and Immunogenicity Analysis of a Newcastle Disease Virus (NDV-HXP-S) Expressing the Spike Protein of SARS-CoV-2 in Sprague Dawley Rats |
| title_full |
Safety and Immunogenicity Analysis of a Newcastle Disease Virus (NDV-HXP-S) Expressing the Spike Protein of SARS-CoV-2 in Sprague Dawley Rats |
| title_fullStr |
Safety and Immunogenicity Analysis of a Newcastle Disease Virus (NDV-HXP-S) Expressing the Spike Protein of SARS-CoV-2 in Sprague Dawley Rats |
| title_full_unstemmed |
Safety and Immunogenicity Analysis of a Newcastle Disease Virus (NDV-HXP-S) Expressing the Spike Protein of SARS-CoV-2 in Sprague Dawley Rats |
| title_sort |
safety and immunogenicity analysis of a newcastle disease virus (ndv-hxp-s) expressing the spike protein of sars-cov-2 in sprague dawley rats |
| publisher |
Frontiers Media S.A. |
| publishDate |
2021 |
| url |
https://doaj.org/article/5b32844202bb44e5b26127bad0eeb6d7 |
| work_keys_str_mv |
AT johnstonetcheou safetyandimmunogenicityanalysisofanewcastlediseasevirusndvhxpsexpressingthespikeproteinofsarscov2inspraguedawleyrats AT arielraskin safetyandimmunogenicityanalysisofanewcastlediseasevirusndvhxpsexpressingthespikeproteinofsarscov2inspraguedawleyrats AT gagandeepsingh safetyandimmunogenicityanalysisofanewcastlediseasevirusndvhxpsexpressingthespikeproteinofsarscov2inspraguedawleyrats AT hisaakikawabata safetyandimmunogenicityanalysisofanewcastlediseasevirusndvhxpsexpressingthespikeproteinofsarscov2inspraguedawleyrats AT dominikabielak safetyandimmunogenicityanalysisofanewcastlediseasevirusndvhxpsexpressingthespikeproteinofsarscov2inspraguedawleyrats AT weinasun safetyandimmunogenicityanalysisofanewcastlediseasevirusndvhxpsexpressingthespikeproteinofsarscov2inspraguedawleyrats AT irenegonzalezdominguez safetyandimmunogenicityanalysisofanewcastlediseasevirusndvhxpsexpressingthespikeproteinofsarscov2inspraguedawleyrats AT dnoahsather safetyandimmunogenicityanalysisofanewcastlediseasevirusndvhxpsexpressingthespikeproteinofsarscov2inspraguedawleyrats AT dnoahsather safetyandimmunogenicityanalysisofanewcastlediseasevirusndvhxpsexpressingthespikeproteinofsarscov2inspraguedawleyrats AT dnoahsather safetyandimmunogenicityanalysisofanewcastlediseasevirusndvhxpsexpressingthespikeproteinofsarscov2inspraguedawleyrats AT adolfogarciasastre safetyandimmunogenicityanalysisofanewcastlediseasevirusndvhxpsexpressingthespikeproteinofsarscov2inspraguedawleyrats AT adolfogarciasastre safetyandimmunogenicityanalysisofanewcastlediseasevirusndvhxpsexpressingthespikeproteinofsarscov2inspraguedawleyrats AT adolfogarciasastre safetyandimmunogenicityanalysisofanewcastlediseasevirusndvhxpsexpressingthespikeproteinofsarscov2inspraguedawleyrats AT adolfogarciasastre safetyandimmunogenicityanalysisofanewcastlediseasevirusndvhxpsexpressingthespikeproteinofsarscov2inspraguedawleyrats AT adolfogarciasastre safetyandimmunogenicityanalysisofanewcastlediseasevirusndvhxpsexpressingthespikeproteinofsarscov2inspraguedawleyrats AT peterpalese safetyandimmunogenicityanalysisofanewcastlediseasevirusndvhxpsexpressingthespikeproteinofsarscov2inspraguedawleyrats AT peterpalese safetyandimmunogenicityanalysisofanewcastlediseasevirusndvhxpsexpressingthespikeproteinofsarscov2inspraguedawleyrats AT floriankrammer safetyandimmunogenicityanalysisofanewcastlediseasevirusndvhxpsexpressingthespikeproteinofsarscov2inspraguedawleyrats AT floriankrammer safetyandimmunogenicityanalysisofanewcastlediseasevirusndvhxpsexpressingthespikeproteinofsarscov2inspraguedawleyrats AT juanmanuelcarreno safetyandimmunogenicityanalysisofanewcastlediseasevirusndvhxpsexpressingthespikeproteinofsarscov2inspraguedawleyrats |
| _version_ |
1718420905065971712 |